enteroporc coli
ceva santé animale - inactivated fimbrial adhesins of escherichia coli f4ab, inactivated fimbrial adhesins of escherichia coli f4ac, inactivated fimbrial adhesins of escherichia coli f5, inactivated fimbrial adhesins of escherichia coli f6 - imunológicos para suidae - porcos - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6.
prevexxion rn
boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - imunologias para aves - frango - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).
enteroporc coli ac
ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - porcos - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:- clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6- clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins- clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.
donjon
bayer ag - pó molhável (wp) com 2% de trichoderma asperellum e 2% de trichoderma gamsii
fatrovax rhd
fatro s.p.a - rabbit hemorrhagic disease virus 2 vp1ab, rabbit hemorrhagic disease virus vp1a - imunológicos para leporidae - coelhos - for active immunisation of rabbits from the age of 28 days to reduce mortality, infection, clinical signs and organ lesions of rabbit haemorrhagic disease caused by rhdv1 and rhdv2.
nuvaxovid
novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. o uso desta vacina deve ser de acordo com as recomendações oficiais. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. o uso desta vacina deve ser de acordo com as recomendações oficiais.
cefoxitina labesfal 500 mg/2 ml pó e solvente para solução injetável
labesfal - laboratórios almiro, s.a. - cefoxitina - pó e solvente para solução injetável - 500 mg/2 ml - cefoxitina sódica 525 mg - cefoxitin - genérico - duração do tratamento: curta ou média duração
cefotaxima hikma 1000 mg/4 ml pó e solvente para solução injetável
hikma farmacêutica (portugal), s.a. - cefotaxima - pó e solvente para solução injetável - 1000 mg/4 ml - cefotaxima sódica 1050 mg - cefotaxime - n/a - duração do tratamento: curta ou média duração
ciprofloxacina ratiopharm 750 mg comprimidos revestidos comprimido revestido por película
ratiopharm - comércio e indústria de produtos farmacêuticos, lda. - ciprofloxacina - comprimido revestido por película - 750 mg - ciprofloxacina, cloridrato mono-hidratado 874.5 mg - ciprofloxacin - genérico - duração do tratamento: curta ou média duração
tobramicina altan 300 mg/5 ml solução para inalação por nebulização
altan pharmaceuticals, s.a. - tobramicina - solução para inalação por nebulização - 300 mg/5 ml - tobramicina 60 mg/ml - tobramycin - n/a - duração do tratamento: curta ou média duração